COMPARATIVE STUDY
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Long-term prognosis for symptomatic (secondarily) generalized epilepsies: a population-based study.

Epilepsia 2007 June
PURPOSE: To describe the long-term outcome of childhood-onset secondarily generalized epilepsies (SGEs).

METHODS: Children were identified from the Nova Scotia population-based epilepsy study (n=692). Onset of epilepsy was between 1977 and 1985, and follow-up was mainly in 2003. SGE was defined as having a mixture of more than one generalized seizure types including myoclonus, akinetic/atonic, tonic, or atypical absence, plus an interictal EEG with generalized spike-wave (irregular or slow) and/or multifocal spikes.

RESULTS: SGE was identified in 80 children, 11.6% (80 of 692) of all childhood epilepsy. Forty percent did not fit into a currently accepted syndrome (such as Lennox-Gastaut, myoclonic-astatic or West). Seizure onset was in the first year of life in 60%, with only 9% later free of intellectual or physical handicap. Sixty-five percent (11 of 17) with Lennox-Gastaut had preceding West syndrome. During a median follow-up of 20 years, mortality was 24% (n=19), and 53% (n=42) had persistently intractable seizures. Surprisingly, 22 (28%) had >or=5 years of terminal remission (West, 31%, 10 of 32; Lennox-Gastaut, 0, none of four; myoclonic-astatic, 56%, five of nine; undefined, 31%, 10 of 32). At the end of follow-up, nearly 90% of patients fell into one of three outcome categories: death, 19 (24%); alive with intractable epilepsy, 31 (39%); or in remission for >or=5 years, 21 (26%).

CONCLUSIONS: Many children with SGE have ill-defined epilepsy syndromes. SGE is characterized by early age at onset, high rates of handicap, intractability, and death, although one third achieve complete seizure control with a long terminal remission.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app